Signature Equity Partners’s Cytokinetics CYTK Stock Holding History

Signature Equity Partners’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$767	Buy	+9	New	+$646	﹤0.01%	1360

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Signature Equity Partners's CYTK Position: Q2 2026 in Review

Signature Equity Partners opened a new position in Cytokinetics (CYTK) in Q2 2026: 9 shares worth $767. The stake represents ﹤0.01% of the portfolio and ranks #1360 among its holdings.

482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Signature Equity Partners held 9 shares of Cytokinetics worth $767 as of Q2 2026.
Cytokinetics was a new Signature Equity Partners position in Q2 2026.
Cytokinetics made up ﹤0.01% of Signature Equity Partners's portfolio in Q2 2026, its #1360 holding.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.